Who owns REVANCE THERAPEUTICS INC?
- CUSIP Number: 761330ab5
Tip: Access positions for across all investors
Analyze quarterly positions in Revance Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Revance Therapeutics stock
Who bought or sold REVANCE THERAPEUTICS INC this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Franklin Resources | 44M | $34M | 0% | Dec 2023 |
|
D. E. Shaw & Co | 38M | $29M | 0% | Dec 2023 |
|
Graham Capital Management | 32M | $24M | 0% | Dec 2023 |
|
Context Capital Management | 31M | $24B | 171164% | Dec 2023 |
|
Aviva | 22M | $17M | -8% | Dec 2023 |
|
Highbridge Capital Management | 20M | $14B | -5% | Dec 2023 |
|
SSI Investment Management | 7.8M | $6.0M | 14% | Dec 2023 |
|
Calamos Advisors | 4.0M | $3.0M | 0% | Dec 2023 |
|
Amundi | 3.4M | $2.5M | 0% | Dec 2023 |
|
Credit Suisse | 2.0M | $1.8M | 0% | Dec 2023 |
|
CSS | 1.7M | $1.3M | -71% | Dec 2023 |
|
Citigroup | 500k | $380k | 0% | Dec 2023 |
|
First Hawaiian Bank | 190k | $138k | 73% | Mar 2024 |
|
William Blair $ Company | 25k | $19k | 0% | Dec 2023 |
|
Barclays | 19k | $14k | -99% | Dec 2023 |
|
Who sold out of Revance Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Capstone Investment Advisors | Sep 2023 | 7.5M | $6.1M |
Readystate Asset Management | Sep 2023 | 5.0M | $4.0M |
Wolverine Asset Management | Sep 2023 | 2.1M | $1.6M |
Bank Of Montreal | Sep 2023 | 1.5M | $1.8M |